๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Neuromyelitis Optica Spectrum Disorder
Clinical trial register · United States · industry-sponsored

Neuromyelitis Optica Spectrum Disorder Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
Massachusetts 4 Texas 3 Colorado 2 District of Columbia 2 North Carolina 2
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
7 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNAยฎ During Pregnancy
NCT05909761Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Amgen
Observational
60
Colorado
2026-10-15
By invitation
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
NCT06374264Neuromyelitis Optica Spectrum Disorder
MedRhythms, Inc.
Not applicable
30
Georgia, Massachusetts
2024-11-12
Active, closed
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06180278Neuromyelitis Optica Spectrum Disorder
Amgen
Phase 4
32
Michigan, Texas
2024-04-02
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
District of Columbia, Massachusetts, North Carolina, Ohio, Texas, Wisconsin
2024-02-01
Recruiting
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
NCT05549258Neuromyelitis Optica Spectrum Disorder
Amgen
Phase 2
15
California, Massachusetts, Texas
2023-07-03
Active, closed
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT05346354Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
Phase 2/3
12
District of Columbia, Florida, Massachusetts, North Carolina, Pennsylvania
2022-06-23
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/neuromyelitis-optica-spectrum-disorder

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.